MedTrace Logo

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

NCT06913218 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-04-06

No results posted yet for this study

Summary

To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC

Conditions

  • Pancreas Cancer
  • Pancreas Cancer, Duct Cell Adenocarcinoma

Interventions

BIOLOGICAL

AK154

AK154 is neotigeon personalized mRNA vaccine

BIOLOGICAL

Cadonilimab

a PD-1/CTLA-4 bispecific antibody

BIOLOGICAL

Ivonescimab (SMT112 or AK112) Injection

a PD-1/VEGF bi-specific antibody

DRUG

mFOLFORINOX

mFOLFIRINOX:Fluorouracil+leucovorin+Irinotecan+Oxaliplatin

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • Akeso

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-22
Primary Completion
2028-02-23
Completion
2028-11-06

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06913218 on ClinicalTrials.gov